Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351263 | 1.00 | PGD (0.35) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL7181932 | 1.00 | PGD (0.35) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL13007214 | 0.84 | TDP1 (0.44) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL7277806 | 0.84 | CYP2D6 (0.32) | PGDCA1CA2CA7CYP2D6 | |
| SCHEMBL10703266 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL12526882 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL28052779 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL28052674 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL27891039 | 0.80 | CYP2D6 (0.32) | CA1CA2CA7CYP2D6MEN1 | |
| SCHEMBL29943608 | 0.80 | TDP1 (0.44) | PGDCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276244-B | Preparation method of carboxylic acid compound and metal salt derivative thereof | 苏州汉酶生物技术有限公司 | 2024-02-27 | — | — | CN | claimed |
| JP-10298142-A | — | — | None | — | — | JP | disclosed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4031521-B1 | CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-100441594-C | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | AVENTIS PHARMA GMBH (DE) | 2008-12-10 | — | — | CN | disclosed |
| CN-101090894-A | Macrocyclic compounds and compositions useful as BACE inhibitors | NOVARTIS AG (CH) | 2007-12-19 | — | — | CN | disclosed |
| CN-101087820-A | Polymer composition, plastic optical fiber, plastic optical cable, and method for producing plastic optical fiber | MITSUBISHI RAYON CO (JP) | 2007-12-12 | — | — | CN | disclosed |
| US-7186741-B2 | Neurotensin active 2,3,diaryl-pyrazolidine derivatives | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-03-06 | — | — | US | disclosed |
| US-7186741-B2 | Neurotensin active 2,3,diaryl-pyrazolidine derivatives | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-03-06 | — | — | US | disclosed |
| CN-1775801-A | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | AVENTIS PHARMA GMBH (DE) | 2006-05-24 | — | — | CN | disclosed |
| CN-1237075-C | Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction | AVENTIS PHARMA GMBH (DE) | 2006-01-18 | — | — | CN | disclosed |
| WO-2003078400-A1 | NEUROTENSIN ACTIVE 2,3-DIARYL-PYRAZOLIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-09-25 | — | — | WO | disclosed |
| CN-1342167-A | Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction | AVENTIS PHARMA GMBH (DE) | 2002-03-27 | — | — | CN | disclosed |
| JP-H10298142-A | PURIFICATION OF 4-TERTIARY-BUTYL METHYLSUCCINATE | MITSUBISHI RAYON CO LTD | 1998-11-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | PGD 3993/4885CA1 4349/4885CA2 4394/4885 |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | PGD 3170/4885CA1 4771/4885CA2 4841/4885 |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | PGD 3919/4885CA1 1170/4885CA2 515/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | PGD 3993/4885CA1 4349/4885CA2 4394/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | PGD 4606/4885CA1 3115/4885CA2 2269/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PGD 3993/4885CA1 4349/4885CA2 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.